These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25614110)

  • 1. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors.
    Shimamoto Y; Hattori Y; Kobayashi K; Teruya K; Sanjoh A; Nakagawa A; Yamashita E; Akaji K
    Bioorg Med Chem; 2015 Feb; 23(4):876-90. PubMed ID: 25614110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor.
    Yoshizawa SI; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2020 Feb; 28(4):115273. PubMed ID: 31926775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.
    Teruya K; Hattori Y; Shimamoto Y; Kobayashi K; Sanjoh A; Nakagawa A; Yamashita E; Akaji K
    Biopolymers; 2016 Nov; 106(4):391-403. PubMed ID: 26572934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.
    Kumar V; Tan KP; Wang YM; Lin SW; Liang PH
    Bioorg Med Chem; 2016 Jul; 24(13):3035-3042. PubMed ID: 27240464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.
    Liu W; Zhu HM; Niu GJ; Shi EZ; Chen J; Sun B; Chen WQ; Zhou HG; Yang C
    Bioorg Med Chem; 2014 Jan; 22(1):292-302. PubMed ID: 24316352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
    Park JY; Kim JH; Kwon JM; Kwon HJ; Jeong HJ; Kim YM; Kim D; Lee WS; Ryu YB
    Bioorg Med Chem; 2013 Jul; 21(13):3730-7. PubMed ID: 23647823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
    Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
    Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
    Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.
    Jacobs J; Grum-Tokars V; Zhou Y; Turlington M; Saldanha SA; Chase P; Eggler A; Dawson ES; Baez-Santos YM; Tomar S; Mielech AM; Baker SC; Lindsley CW; Hodder P; Mesecar A; Stauffer SR
    J Med Chem; 2013 Jan; 56(2):534-46. PubMed ID: 23231439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
    Du QS; Sun H; Chou KC
    Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
    Nguyen TT; Ryu HJ; Lee SH; Hwang S; Breton V; Rhee JH; Kim D
    Bioorg Med Chem Lett; 2011 May; 21(10):3088-91. PubMed ID: 21470860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.